Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET.
The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at ww.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 30 days following the event.
Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481 Media Contact: Ian Stone Canale Communications [email protected] 619-849-5388